You are here: Annual Meeting / 2017 / Programme
Thursday, 21.09.2017

Meeting Exhibitors

Program

PRE-MEETING EVENT

WEDNESDAY, April 26th, 2017

13.00-19.00 SCNP-CINP EDUCATIONAL WORKSHOP

UPDATE ON NEUROPSYCHOPHARMACOLOGY

(seats limited to 40, priority given to clinicians & participants in the Congress)

ADHD - from diagnosis to intervention
Workshop speakers & discussants

Michael Huss (Mainz, Germany)

Jacob Ørnberg (Aalborg, Denmark)

Gregers Wegener (Aarhus, Denmark)

Bo Söderpalm (Gothenburg, Sweden)

THURSDAY, APRIL 27th, 2017

09.00- REGISTRATION OPENS 

09.00-10.00 SCNP GENERAL ASSEMBLY 

10.00-10.05 SCNP 2017 Opening

President’s Welcome

Gregers Wegener (Aarhus, Denmark) 

10.05-10.50 OPENING LECTURE

SCNP 2016 Opening Lecture

Moderator: Gregers Wegener (Aarhus, Denmark)

A perspective on ethical and practical aspects of forced treatment.
Pall Mathiasson (Reykjavik, Iceland) 

10.50-11.00 STRETCHING LEGS BREAK 

11.00-13.00 PLENARY SESSION

Update on new drugs

Moderators: Ole A. Andreassen (Oslo, Norway), Anders Tingström (Lund, Sweden)

Guanfacin – pharmacological profile and clinical use
Michael Huss (Mainz, Germany)

NMDA receptor modulators as possible treatments for CNS disorders

Torsten Meldgaard Madsen (Chicago, USA)

Recent advances in targeting α2-adrenergic receptors for new neuropsychiatric therapeutics  
Mo Shahid (Nottingham, United Kingdom)

13.00-13.45 LUNCH 

13.45-15.15 SCNP YOUNG SCIENTIST SYMPOSIUM

Moderators: Gregers Wegener (Aarhus, Denmark) & Ole A. Andreassen (Oslo, Norway)

Speakers to be announced (based on competition) 

15.15-15.45 COFFEE BREAK 

15.45-16.30 SCNP LECTURE

Moderator: Páll Matthíasson (Reykjavik, Iceland)

Progressive neuroanatomical abnormalities in the psychoses and the impact of psychopharmacology.
Colm MacDonald (Galway, Ireland) 

16.30-17.15 SCNP LECTURE

Moderator: Olli Kampman (Tampere, Finland)

Erythropoietin targeting cognitive impairment: studies in mood disorders and methodological implications

Kamilla W. Miskowiak (Copenhagen, Denmark) 

17.15-18.45 POSTER SESSION

Refreshments 

19.45- SCNP 2017 Dinner

Restaurant Nose2tail, Copenhagen

FRIDAY, APRIL 28th, 2017

09.00-09.45 SCNP LECTURE

Moderator: Anders Tingström (Lund, Sweden)

Update on rapid acting antidepressant intervention: from ketamine to future strategies

Gregers Wegener (Aaarhus, Denmark)

09.45-10.15 COFFEE BREAK 

10.15-11.45 PLENARY SESSION

Treatment responses and pathophysiology in mood disorders

Moderators: Ole Andreassen (Oslo) & Bo Söderpalm (Gothenburg, Sweden)

Biomarkers of lithium response

Thomas G Schulze (Munich, Germany)

Quinolinic acid and suicide

Sophie Erhardt (Stockholm, Sweden)

Neuropeptide Y and neuropeptide S in pathophysiology and treatment of depression and PTSD

Aleksander A. Mathé (Stockholm, Sweden)

11.45-13.15 PLENARY SESSION

Recent new updates on ADHD and Autism spectrum disorders

Moderators: Olli Kampman (Tampere, Finland) & Bo Söderpalm (Gpthenburg, Sweden)

ADHD in criminal offenders: short and long term effects of treatment

Ylva Ginsberg (Stockholm, Sweden)

How to evaluate the treatment of ADHD in adult

Mats Fredriksen (Vestfold, Norway)

Treatment and pathophysiology of Autism spectrum disorders

Lars Westberg (Gothenburg, Sweden)

13.15-14.00 LUNCH 

14.00-14.45 SCNP LECTURE

Moderator: Olli Kampman (Tampere, Finland)

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

Andrea Cipriani (Oxford, UK)

15.00-15.15 LEG STRETCHING BREAK 

15.15-16.45 PLENARY SESSION

Effects of Glucagon-like Peptide-1 (GLP-1) Receptor Stimulation - a Molecular Target relevant for Psychiatry

Moderators: Anders Fink-Jensen (Copenhagen, Denmark) & Gregers Wegener (Aarhus, Denmark)

Effects of glucagon-like peptide-1 (GLP-1) receptor stimulation on alcohol consumption in alcohol-preferring vervet monkeys

Maurice Ptito (Copenhagen, Denmark)

GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment

Vallo Volke (Tartu, Estonia)

The GLP-1 receptor agonist liraglutide improves metabolic outcomes in antipsychotic-treated patient

Anders Fink-Jensen (Copenhagen, Denmark) 

16.45 CONCLUSION OF THE MEETING